|
시장보고서
상품코드
2091330
국소분절사구체경화증(FSGS) 치료 시장 규모, 점유율, 성장 분석 : 질환 유형별, 질환 관리별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Focal Segmental Glomerulosclerosis FSGS Treatment Market Size, Share, and Growth Analysis, By Disease Type (Primary FSGS, Secondary FSGS), By Disease Management (Diagnosis, Treatment), By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 국소분절사구체경화증(FSGS) 치료 시장 규모는 2024년에 31억 2,000만 달러로 평가되었으며, 2025년 32억 7,000만 달러에서 2033년까지 47억 6,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 4.8%로 성장할 것으로 전망됩니다.
세계 국소분절사구체경화증(FSGS) 치료 시장은 이 신증후군으로 고통받는 환자의 단백뇨를 줄이고 신장 기능을 유지하는 것을 목적으로 하는 의약품, 생물학적 제제 및 지지요법에 초점을 맞추고 있습니다. 말기 신장질환의 발생률 증가는 의료 분야에서 큰 부담과 충족되지 않은 임상적 요구를 여실히 드러내고 있습니다. 치료 현황은 제네릭 면역억제제에서 표적 치료로 진화하고 있으며, 특히 기저세포 손상이나 면역 조절 이상에 대처하는 신약의 도입이 활발히 진행되고 있습니다. 스파르센탄을 비롯한 혁신적인 치료법에 대한 파이프라인 확대와 유리한 보험 급여율이 시장 성장을 견인하고 있습니다. 또한, AI는 신약 개발 촉진, 임상시험의 효율화, 환자 맞춤형 치료를 통해 이 분야를 혁신하고 있으며, 지속적인 투자를 유치하고 시장 확대를 뒷받침하고 있습니다.
세계 국소분절사구체경화증(FSGS) 치료 시장의 성장요인
국소분절사구체경화증(FSGS)에 대한 임상적 인식이 높아지고 진단법이 발전함에 따라, 이 질환을 조기에 발견할 수 있게 되었습니다. 이러한 진전에 따라 새로운 치료법의 혜택을 받을 수 있는 환자층이 확대되면서, 각 제약사는 이 전문 분야에 연구 개발을 집중하고 있습니다. 그 결과, 시장 성장이 촉진될 뿐만 아니라 치료 과정 전반에 걸쳐 투자가 유치되고 있습니다. 또한, 이러한 발전은 학술 기관과 생명공학 기업 간의 협력을 촉진하고, 지식 공유와 임상시험 참여를 가속화하고 있습니다. 그 결과, 혁신적인 치료법 파이프라인이 강화되어 세계 시장의 지속적인 확장을 뒷받침하고 있습니다.
세계 국소분절사구체경화증(FSGS) 치료 시장의 제약요인
국소분절사구체경화증(FSGS)에 대한 혁신적인 치료법의 높은 비용은, 특히 보험 급여 옵션이 제한적인 지역에서, 의료 시스템과 환자 모두에게 심각한 경제적 부담이 되고 있습니다. 이러한 경제적 부담은 이러한 치료법의 광범위한 채택과 임상 현장에의 도입을 저해하고 있습니다. 또한, 보험사는 신약을 승인하기 전에 광범위한 의료경제성 평가를 의무화하는 경우가 많으며, 그 결과 보험 적용 목록에 등재되는 시기가 늦어질 가능성이 있습니다. 본인 부담금이 높다는 점도 처방된 치료 계획에 대한 환자의 순응도 저하로 이어지며, 명백한 임상적 이점이 있음에도 불구하고 전반적인 수요 증가를 억제하는 요인이 됩니다. 게다가 지역 간 보험 적용 범위의 격차가 환자 간 접근성 격차를 초래하여 시장 성장을 더욱 저해하고 있습니다.
세계 국소분절사구체경화증(FSGS) 치료 시장의 동향
세계 국소분절사구체경화증(FSGS) 치료 시장에서는 유전체 시퀀싱 및 바이오마커 연구 분야의 획기적인 발전이 치료 전략을 혁신하는 가운데, 정밀 의학으로의 뚜렷한 전환 추세가 나타나고 있습니다. 각 제약사는 FSGS 치료제 개발을 정밀 종양학의 틀에 점점 더 부합하도록 조정하면서, 포도세포 손상과 관련된 분자 경로를 특이적으로 표적으로 삼는 치료법에 주력하고 있습니다. 이러한 접근 방식을 통해 임상의는 개별 유전자 프로파일에 기반하여 치료를 최적화할 수 있게 되며, 이는 치료 성과 향상과 시행착오 최소화로 이어집니다. 헬스케어 업계에서 맞춤형 의료에 대한 관심이 높아지면서 투자자들의 관심을 불러일으키고 있으며, 전 세계적으로 전문적인 연구개발 이니셔티브에 대한 제휴 활동과 자금 지원이 확대되어, 결과적으로 이 틈새 시장의 혁신을 촉진하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 국소분절사구체경화증(FSGS) 치료 시장 규모 : 질환 유형별
세계의 국소분절사구체경화증(FSGS) 치료 시장 규모 : 질환 관리별
세계의 국소분절사구체경화증(FSGS) 치료 시장 규모 : 최종사용자별
세계의 국소분절사구체경화증(FSGS) 치료 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Focal Segmental Glomerulosclerosis Fsgs Treatment Market size was valued at USD 3.12 Billion in 2024 and is poised to grow from USD 3.27 Billion in 2025 to USD 4.76 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).
The global focal segmental glomerulosclerosis (FSGS) treatment market focuses on pharmaceuticals, biologics, and supportive care that aim to reduce proteinuria and maintain renal function in patients suffering from this nephrotic syndrome. The rising incidence of end-stage renal disease highlights a significant healthcare burden and unmet clinical demands. The treatment landscape has evolved from generic immunosuppressants to targeted therapies, especially with the introduction of novel agents that address podocyte injury and immune dysregulation. The expanding pipeline and favorable reimbursement rates for innovative treatments, such as sparsentan, are driving growth. Additionally, AI is transforming this sector by enhancing drug discovery, improving clinical trial efficiency, and personalizing patient treatment, which attracts ongoing investments and bolsters market expansion.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Focal Segmental Glomerulosclerosis Fsgs Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Focal Segmental Glomerulosclerosis Fsgs Treatment Market Segments Analysis
Global Focal Segmental Glomerulosclerosis Fsgs Treatment Market size was valued at USD 3.12 Billion in 2024 and is poised to grow from USD 3.27 Billion in 2025 to USD 4.76 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).
Driver of the Global Focal Segmental Glomerulosclerosis Fsgs Treatment Market
The increasing clinical awareness of focal segmental glomerulosclerosis (FSGS) coupled with advancements in diagnostic methods allows for earlier detection of this condition. This enhancement broadens the patient demographic that can benefit from new therapies, driving pharmaceutical companies to focus their research and development efforts in this specialized area. Consequently, this not only fuels market growth but also attracts investment throughout the treatment process. Furthermore, such progress encourages collaborations between academic institutions and biotechnology companies, promoting the sharing of knowledge and expediting clinical trial participation, which in turn strengthens the pipeline of innovative treatment options and supports sustained global market expansion.
Restraints in the Global Focal Segmental Glomerulosclerosis Fsgs Treatment Market
The high cost of innovative treatments for Focal Segmental Glomerulosclerosis (FSGS) presents significant affordability issues for both healthcare systems and patients, especially in areas with limited reimbursement options. This financial burden hinders the broad adoption and integration of such therapies into practice. Moreover, payers often mandate extensive health-economic evaluations before approving new drugs, which can result in delays for formulary inclusion. High out-of-pocket expenses can also lead to decreased patient adherence to prescribed regimens, constraining overall demand growth despite the evident clinical advantages. Additionally, disparities in insurance coverage between regions contribute to unequal patient access, further impeding market growth.
Market Trends of the Global Focal Segmental Glomerulosclerosis Fsgs Treatment Market
The Global Focal Segmental Glomerulosclerosis (FSGS) Treatment market is witnessing a significant trend towards precision medicine, as breakthroughs in genomic sequencing and biomarker research reshape therapeutic strategies. Pharmaceutical companies are increasingly aligning their FSGS drug development with precision-oncology frameworks, focusing on therapies that specifically target molecular pathways associated with podocyte injury. This approach enables clinicians to tailor treatments based on individual genetic profiles, enhancing treatment outcomes and minimizing trial-and-error. The healthcare industry's emphasis on personalized care is stimulating investor interest, leading to greater partnership activities and financial support for specialized research and development initiatives worldwide, thereby fostering innovation in this niche market.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Focal Segmental Glomerulosclerosis FSGS Treatment Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Primary FSGS
- Secondary FSGS
- Genetic FSGS
Global Focal Segmental Glomerulosclerosis FSGS Treatment Market Size by Disease Management & CAGR (2026-2033)
- Market Overview
- Diagnosis
- Kidney Biopsy
- Creatinine Test
- Urine Protein Tests
- Genetic Testing
- Treatment
- Drug Therapy
- Dialysis
- Kidney Transplant
Global Focal Segmental Glomerulosclerosis FSGS Treatment Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Transplant Centers
- Specialty Clinics
- Nephrology Practices
- Dialysis Centers
- Academic Institutes
- Research Institutes
Global Focal Segmental Glomerulosclerosis FSGS Treatment Market Size & CAGR (2026-2033)
- North America (Disease Type, Disease Management, End User)
- US
- Canada
- Europe (Disease Type, Disease Management, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Disease Management, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Disease Management, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Disease Management, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Travere Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vertex Pharmaceuticals Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ChemoCentryx Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Goldfinch Bio Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chinook Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Angion Biomedica Corp.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Complexa Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dimerix Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Variant Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- River 3 Renals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Retrophin Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Omeros Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
